Oppenheimer (NYSE:OPY – Get Rating) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued on Wednesday.
Oppenheimer Stock Up 1.0 %
Shares of NYSE OPY opened at $37.66 on Wednesday. Oppenheimer has a 52-week low of $28.41 and a 52-week high of $49.32. The company’s 50 day moving average price is $37.99 and its 200-day moving average price is $41.22. The company has a market capitalization of $416.52 million, a P/E ratio of 11.99 and a beta of 1.15. The company has a debt-to-equity ratio of 0.14, a quick ratio of 0.92 and a current ratio of 1.35.
In related news, insider Dennis P. Mcnamara sold 12,120 shares of the company’s stock in a transaction that occurred on Friday, March 3rd. The stock was sold at an average price of $44.53, for a total value of $539,703.60. Following the transaction, the insider now owns 24,324 shares in the company, valued at $1,083,147.72. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 32.49% of the company’s stock.
Institutional Inflows and Outflows
Oppenheimer Holdings, Inc engages as a middle-market investment bank and full-service broker-dealer. It operates through the following segments: Private Client, Asset Management, Capital Markets, and Corporate/Other. The Private Client segment consists of commissions and a proportionate amount of fee income earned on assets under management (AUM), net interest earnings on client margin loans and cash balances, fees from money market funds, custodian fees, net contributions from stock loan activities and financing activities, and direct expenses.
- Get a free copy of the StockNews.com research report on Oppenheimer (OPY)
- It’s Time To Take Another Bite Of Take-Two Interactive
- Zoetis Declares New Dividend, Hinting At Undervaluation
- Good News For Walmart Isn’t So Great For Everybody Else
- Eagle Materials, Answering America’s Building Supply Needs
- Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Receive News & Ratings for Oppenheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oppenheimer and related companies with MarketBeat.com's FREE daily email newsletter.